AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca: Great Portfolio, But Not A Great Price
AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and Ultomiris show impressive growth, but looming patent expiries and legal risks threaten future revenues. Heavy R&D investment and strategic moves into cell/gene therapy and AI-driven drug discovery support AstraZeneca's long-term growth outlook.
Ex-dividend day weighs heavily on the FTSE this week
Thursday is ex-dividend day in London and this week there was a heavyweight billing that knocked the FTSE 100 sideways, including companies such as AstraZeneca PLC (LSE:AZN), NatWest Group PLC (LSE:NWG) and Rolls-Royce Holdings PLC (LSE:RR.). There were 18.3 points collectively shaved off the index as a result of 12 blue-chips going ex-dividend on the day, when investors who purchase shares today are no longer entitled to their latest dividend payouts.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AstraZeneca gets clean bill of health from leading investment bank
AstraZeneca PLC (LSE:AZN) shares have caught the attention of UBS, which reiterated its 'buy' rating and raised its price target to 14,200p, implying over 27% upside from the current level, after a solid set of second-quarter results. The drugmaker beat the Swiss Bank's estimates on both sales and operating profit, helped by stronger-than-expected growth in US oncology and a rebound in its rare disease division.
AstraZeneca PLC (AZN) Q2 2025 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN ) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Andrew P. Barnett - Head of Investor Relations Aradhana Sarin - CFO & Executive Director David Fredrickson - Executive Vice-President of Oncology Haematology Business Unit Iskra Reic - Executive Vice President of International Marc Dunoyer - CEO of Alexion & Chief Strategy Officer Pascal Claude Roland Soriot - CEO & Executive Director Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D Susan Mary Galbraith - Executive Vice President of Oncology R&D Conference Call Participants Gonzalo Artiach Castanon - Danske Bank A/S, Research Division James Daniel Gordon - JPMorgan Chase & Co, Research Division Luisa Caroline Hector - Joh.
AstraZeneca gets £3.3bn lift after upbeat results and steady outlook
AstraZeneca PLC (LSE:AZN) saw £3.3 billion added to its market value after delivering a strong set of half-year results and confirming its guidance for 2025. The group reported second-quarter revenue of $14.46 billion, up 12%, driven by double-digit gains in oncology and biopharmaceuticals.
Astrazeneca (AZN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
AZN's second-quarter revenues beat on strong drug sales across Oncology and CVRM despite in-line earnings.
AstraZeneca Stock Rises as US, Cancer Drug Growth Lifts Q2 Results
AstraZeneca (AZN) shares are rising in premarket trading Tuesday after the pharma giant beat second-quarter estimates on strong U.S. growth and demand for its cancer drugs.
AstraZeneca maintains outlook as pipeline delivers strong late-stage results
AstraZeneca PLC (LSE:AZN) has reiterated its full-year guidance for 2025, following a robust set of results for the second quarter and first half, and pointed to a series of significant late-stage trial successes across its research and development pipeline. The pharmaceutical group reported total revenue of $14.46 billion for the second quarter, up 12% compared with the same period last year at actual exchange rates, driven by double-digit growth in oncology and biopharmaceuticals.
AstraZeneca beats second-quarter profit expectations, maintains outlook
AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney disease drugs, but maintained its full-year forecast as pricing pressures and global trade risks remain challenges.
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Astrazeneca (AZN) closed at $72.66, indicating a -1.38% shift from the previous trading day.
